Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LMB-100 with or without Nab-Paclitaxel in Pancreatic Cancer and Solid Tumors
NCT02810418Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2016
- Primary completion
- Jan 2019
- Modality
- Antibody-Drug Conjugates (ADCs), Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of LMB-100 in pancreatic ductal adenocarcinoma (PDAC), mesothelioma, solid tumor, sponsored by National Cancer Institute. Started Aug 2016; status: completed.
02
Drugs
LMB-100
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)mesotheliomasolid tumor
Beyond the preview
Go deeper on NCT02810418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02810418.